artemisinin  (MedChemExpress)

Journal: Cell Communication and Signaling : CCS

Article Title: RAB40C recruiting TRIM21 facilitates the progression of hepatocellular carcinoma by stabilizing EGFR

doi: 10.1186/s12964-025-02580-7

Figure Lengend Snippet: Artemisinin, a ligand of RAB40C, displayed a promising potential in HCC therapy. A A 2D model of binding of artemisinin to amino acid residues of RAB40C. B 3D model of RAB40C’s optimal binding mechanism in the protein pocket (artemisinin depicted as colored sticks). C Amino acid residues of RAB40C interacting with the artemisinin in 3D (color sticks). D , E The inhibition effect of artemisinin on EGFR was detected by western blot. F The k63-linked ubiquitination of EGFR by artemisinin was detected by IP analysis. G , H The inhibitory effect of artemisinin on cell viability of HepG2 and Huh7 cells by colony formation assay

Article Snippet: Artemisinin (HY-B0094) was s purchased from MedChemExpress.

Techniques: Binding Assay, Inhibition, Western Blot, Ubiquitin Proteomics, Colony Assay

Journal: Biomolecules and Biomedicine

Article Title: Profiling of sesquiterpenoid fractions from Artemisia annua L. and testing their in vitro anti-SARS-CoV-2 activity

doi: 10.17305/bb.2025.12052

Figure Lengend Snippet: Tandem mass spectra of arteannuin B and artemisinin acquired by ESI-QTOF-MS/MS in positive ion mode. Representative MS/MS spectra used to confirm the identity of the target sesquiterpenoids detected in the Artemisia annua ethanolic extract and subsequent fractions. Panels show the characteristic fragmentation patterns of (A) arteannuin B with precursor ion [M+H] + at m/z 249; and (B) Artemisinin with precursor ion [M+H] + at m/z 283. The observed fragment ions match literature and reference standard data, supporting confident identification and the selectivity of the downstream HSCCC fractionation. MS/MS: Tandem mass spectrometry; ESI: Electrospray ionization; QTOF: Quadrupole time-of-flight; HSCCC: High-speed counter-current chromatography; m/z: Mass-to-charge ratio.

Article Snippet: Authentic artemisinin and arteannuin B standards for compound identification were obtained from Sigma-Aldrich and MedChemExpress.

Techniques: Tandem Mass Spectroscopy, High Speed Counter-current Chromatography, Fractionation, Mass Spectrometry

Journal: Biomolecules and Biomedicine

Article Title: Profiling of sesquiterpenoid fractions from Artemisia annua L. and testing their in vitro anti-SARS-CoV-2 activity

doi: 10.17305/bb.2025.12052

Figure Lengend Snippet: TIC of the crude EtOH extract of Artemisia annua and EIC of arteannuin B. The TIC profile of the crude ethanolic leaf extract (top) provides a molecular fingerprint of the complex mixture, highlighting multiple constituents. The EIC at m/z 249 [M+H] + (bottom) confirms the presence of arteannuin B, detected as a distinct peak at 8.63 min. These results verify arteannuin B as one of the main compounds in the crude extract, thereby supporting its targeted isolation and further fractionation. TIC: Total ion chromatogram; EIC: Extracted ion chromatogram; EtOH: Ethanol; min: Retention time in minutes; m/z: Mass-to-charge ratio; [M+H] + : Protonated molecular ion.

Article Snippet: Authentic artemisinin and arteannuin B standards for compound identification were obtained from Sigma-Aldrich and MedChemExpress.

Techniques: Isolation, Fractionation

Journal: Biomolecules and Biomedicine

Article Title: Profiling of sesquiterpenoid fractions from Artemisia annua L. and testing their in vitro anti-SARS-CoV-2 activity

doi: 10.17305/bb.2025.12052

Figure Lengend Snippet: TIC and EIC of the artemisinin knockout fraction of Artemisia annua . The TIC (top) shows the overall chemical profile of the fraction. The EIC at m/z 249 [M+H] + (middle) confirms arteannuin B at 8.48 min, while the EIC at m/z 305 [M+Na] + (bottom) demonstrates the absence of artemisinin, confirming the selectivity of the fractionation. TIC: Total ion chromatogram; EIC: Extracted ion chromatogram; m/z: Mass-to-charge ratio; [M+H] + : Protonated molecular ion; [M+Na] + : Sodium adduct ion.

Article Snippet: Authentic artemisinin and arteannuin B standards for compound identification were obtained from Sigma-Aldrich and MedChemExpress.

Techniques: Knock-Out, Fractionation

Journal: Biomolecules and Biomedicine

Article Title: Profiling of sesquiterpenoid fractions from Artemisia annua L. and testing their in vitro anti-SARS-CoV-2 activity

doi: 10.17305/bb.2025.12052

Figure Lengend Snippet: Comparative ESI-QTOF-MS/MS spectra (positive ion mode) of arteannuin B: HSCCC fraction vs. reference standard. Overlaid MS/MS spectra for the precursor ion m/z 249 [M+H] + from the arteannuin B fraction (top) and the pure compound (bottom) show matching fragmentation patterns, confirming unambiguous identification and high purity of the isolated fraction obtained by HSCCC. ESI: Electrospray ionization; QTOF: Quadrupole time-of-flight; MS/MS: Tandem mass spectrometry; HSCCC: High-speed counter-current chromatography; m/z: Mass-to-charge ratio; [M+H] + : Protonated molecular ion.

Article Snippet: Authentic artemisinin and arteannuin B standards for compound identification were obtained from Sigma-Aldrich and MedChemExpress.

Techniques: Tandem Mass Spectroscopy, High Speed Counter-current Chromatography, Isolation, Mass Spectrometry

Journal: Biomolecules and Biomedicine

Article Title: Profiling of sesquiterpenoid fractions from Artemisia annua L. and testing their in vitro anti-SARS-CoV-2 activity

doi: 10.17305/bb.2025.12052

Figure Lengend Snippet: Normalized inhibition (%) of the Alpha variant (B.1.1.7 + Q.*; hCoV-19/Bosnia and Herzegovina/VFS-UNSA-LMGFI031/2021; GISAID accession ID: EPI_ISL_1016969) determined by quantitative real-time PCR after exposure of Vero E6 infected monolayers to different concentrations of each tested Artemisia annua L. sample for 48 h. Samples (A) A. annua L. SC-CO 2 extract; (B) A. annua L. EtOH extract; (C) Artemisinin knockout fraction; (D) Arteannuin B fraction; (E) Artemisinin. Data are presented as means of independent replicates ± standard deviations. Statistically significant differences compared to controls (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).

Article Snippet: Authentic artemisinin and arteannuin B standards for compound identification were obtained from Sigma-Aldrich and MedChemExpress.

Techniques: Inhibition, Variant Assay, Real-time Polymerase Chain Reaction, Infection, Knock-Out

Journal: iScience

Article Title: LCN2-mediated ferroptosis resistance in tissue homeostasis and early-stage tumorigenesis of the fallopian tube epithelium

doi: 10.1016/j.isci.2025.112654

Figure Lengend Snippet: LCN2 inhibits ferroptosis in the human FTE organoids (A) Expression of OVGP1 , FOXJ1 , and LCN2 under treatment with a vehicle or approximately 100 nM β-Estradiol on day 8 examined using qPCR ( n = 2, with three technical replicates per sample). (B) Immunohistochemistry of a human FT stained with an anti-LCN2-antibody. Images are shown at both low magnification (scale bar: 200 μm) and high magnification (scale bar: 20 μm). (C) Bright-field images of the human FTE organoids cultured under treatment with ferric ions (5 and 10 mM) or a vehicle for 7 days. (D) Expression of LCN2 in the human FTE organoids and the LCN2-OE organoids examined using qPCR ( n = 2, with three technical replicates per sample). (E) A Bright-field image of the human FTE organoids and the LCN2-OE organoids on day 10. A scale bar indicates 500 μm. (F) Total area of organoids from the human FTE cells or the LCN2-OE cells ( n = 1, with four technical replicates per samples). (G) Number of organoids from the human FTE cells or the LCN2-OE cells ( n = 1, with four technical replicates per samples). (H) Cell viability of the human FTE organoids and the LCN2-OE organoids cultured under treatment with ferric ions (5 and 10 mM) or a vehicle on day 8, normalized to the cell viability under treatment with a vehicle ( n = 1, with three technical replicates per sample). (I) Cell viability of the human FTE organoids and the LCN2-OE organoids treated with 100 and 500 μM artemisinin, or a vehicle, normalized to the cell viability under treatment with a vehicle ( n = 1, with three technical replicates per sample). (J) Cell viability of the human FTE organoids and the LCN2-OE organoids treated with 5 and 10 μM erastin, or a vehicle, normalized to the cell viability under treatment with a vehicle ( n = 1, with three technical replicates per sample). Data are represented as the mean ± SEM, in principle. Statistical analyses were performed using the Student’s t tests for all comparisons. Significance levels are ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

Article Snippet: Artemisinin , Cayman , 11816.

Techniques: Expressing, Immunohistochemistry, Staining, Cell Culture

Journal: iScience

Article Title: LCN2-mediated ferroptosis resistance in tissue homeostasis and early-stage tumorigenesis of the fallopian tube epithelium

doi: 10.1016/j.isci.2025.112654

Figure Lengend Snippet: Carcinogenic p53 dysfunction in human FTE suppresses differentiation and enhances ferroptosis resistance (A) Representative fluorescence immunostaining images of very early-stage high-grade serous carcinoma (HGSC, Stage IA). Sections were stained with DAPI (blue), p53 (red), and LCN2 (green), and a merged image to illustrate co-localization. Scale bars indicate ∼250 μm. (B) LCN2-positive area fractions in the IHC of normal epithelium and epithelial lesions with abnormal p53-staining within 18 human FTE samples (including the HGSC Stage IA sample). The LCN2-positive area was quantified, and the percentage of LCN2-positive area in the total epithelial area of each region was calculated using StrataQuest. The percentages of LCN2-positive area are shown. (C) Bright-field images of the human FTE organoids and the human FTE organoids introduced p53 knockout by CRISPR/Cas9 under Nutilin-3A selection. Scale bars indicate 200 or 500 μm. (D) Expression of TP53 in the human FTE organoids and the p53-knocked single-picked FTE organoids on day 11 examined using qPCR ( n = 2, with three technical replicates per sample). (E) Expression of OVGP1 and FOXJ1 in the human FTE organoids and the p53-knocked single-picked FTE organoids on day 11 examined using qPCR ( n = 2, with three technical replicates per sample). (F) Expression of LCN2 in the human FTE organoids and the p53-knocked single-picked FTE organoids on day 11 examined using qPCR ( n = 2, with three technical replicates per sample). (G) Expression of NF-κB-related genes TNF , IL1A , IL1B , and IL6 in the human FTE organoids and the p53-knocked single-picked FTE organoids on day 11 examined by qPCR ( n = 1, with three technical replicates per sample). (H) Growth curve of the human FTE organoids and the p53-knocked FTE organoids selected by Nutlin-3A, normalized to their growth level on day 2 ( n = 1, with three technical replicates per sample). (I) Proliferation of the human FTE organoids and the p53-knocked FTE organoids selected by Nutlin-3A treated with a vehicle or 500 μM Artemisinin. Data were normalized to those of the vehicle control ( n = 1, with three technical replicates per sample). (J) Schematic representation of the ferroptosis inhibition pathway via LCN2 in normal human FTE and human FTE with p53 dysfunction. This diagram highlights the role of LCN2 in mediating ferroptosis resistance under both conditions. Created with BioRender.com . Data are represented as the mean ± SEM, in principle. Statistical analyses were performed using the paired t-test for B and nonlinear regression with the extra sum-of-squares F test for H, while the Student’s t tests were used for comparisons between two groups in all other cases. Significance levels are ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001.

Article Snippet: Artemisinin , Cayman , 11816.

Techniques: Fluorescence, Immunostaining, Staining, Knock-Out, CRISPR, Selection, Expressing, Control, Inhibition